Title: Update on Fecal Microbiota Transplantation In Inflammatory Bowel Diseases

  • Shawn L. Kwok University of Science, Arts and Technology, College of Medicine, South Mayfield Estate Drive, Olveston, Montserrat.
    Comprehensive Digestive Institute of Nevada Las Vegas, NV.
  • Bridgette Choi Medical Microbiome Institute Las Vegas, NV.
  • Jae H. Choi Medical Microbiome Institute Las Vegas, NV.
  • Satnaam S. Bassi Mountain View Hospital Graduate Medical Education, Las Vegas, NV.
  • David Q. Shih Comprehensive Digestive Institute of Nevada Las Vegas, NV.
    Medical Microbiome Institute Las Vegas, NV.
    Mountain View Hospital Graduate Medical Education, Las Vegas, NV.

Abstract

The microbiome in our digestive tract has beneficial and symbiotic effects on our health. Loss of this diversity may be associated with certain autoimmune diseases such as inflammatory bowel disease, a condition hallmarked by chronic inflammation of the gastrointestin- al tract due to dysregulated immune response to host intestinal mi- croflora. Fecal microbiota transplantation has been effective in treating medically refractory Clostridium difficile infection and is now being studied in other gastrointestinal diseases, including IBD. Several recent meta-analyses have been performed to determine the efficacy of using FMT in patients with Crohn’s disease and Ulcer- ative Colitis. It has also been the focus of small trials in order to treat pouchitis and extraintestinal manifestations of IBD. This article is a systemic review of the up to date clinical trials and meta- analysis focusing on the use of FMT for patients with IBD.

download PDF
Published
2018-11-10
Citation
Shih D. et al. (2018) Update on Fecal Microbiota Transplantation In Inflammatory Bowel Diseases. Science Publishing Group Journal 1(2).
Corresponding author

David Shih
Email: david10021@gmail.com

Full Text